Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Apatinib in Advanced Non-Squamous NSCLC
NCT02515435Phase 2Unknown
- Sponsor
- Tongji University
- Start
- Jan 2015
- Primary completion
- Aug 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of Rivoceranib in Nonsquamous Non-Small Cell Lung Cancer (nsNSCLC), sponsored by Tongji University. Primary endpoint: Objective Response Rate up to 24 months. Status: unknown.
02
Drugs
Rivoceranib
03
Conditions
Nonsquamous Non-Small Cell Lung Cancer (nsNSCLC)
Beyond the preview
Go deeper on NCT02515435.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02515435.